{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:44:57Z","timestamp":1776725097846,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["No. 2208085MH26"],"award-info":[{"award-number":["No. 2208085MH26"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-026-00863-8","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:16:44Z","timestamp":1773314204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid identification of antigen-specific monoclonal antibodies from HIV-1 elite controllers using the Beacon platform"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiangyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengrui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengchao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"863_CR1","first-page":"126","volume":"56","author":"F Barr\u00e9-Sinoussi","year":"2004","unstructured":"Barr\u00e9-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Rev Investig Clin. 2004;56:126\u20139.","journal-title":"Rev Investig Clin"},{"key":"863_CR2","unstructured":"UNAIDS. 2024 global AIDS report\u2014The Urgency of Now: AIDS at a Crossroads. 2024. https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/global-aids-update-2024."},{"key":"863_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105788","volume":"222","author":"AI Schriek","year":"2024","unstructured":"Schriek AI, Aldon YLT, van Gils MJ, de Taeye SW. Next-generation bNAbs for HIV-1 cure strategies. Antiviral Res. 2024;222:105788. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105788.","journal-title":"Antiviral Res"},{"key":"863_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-017-0178-3","volume":"14","author":"Y Ahmed","year":"2017","unstructured":"Ahmed Y, Tian M, Gao Y. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies. AIDS Res Ther. 2017;14:50. https:\/\/doi.org\/10.1186\/s12981-017-0178-3.","journal-title":"AIDS Res Ther"},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1073\/pnas.91.4.1539","volume":"91","author":"ET Sawai","year":"1994","unstructured":"Sawai ET, Baur A, Struble H, Peterlin BM, Levy JA, Cheng-Mayer C. Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci USA. 1994;91:1539\u201343. https:\/\/doi.org\/10.1073\/pnas.91.4.1539.","journal-title":"Proc Natl Acad Sci USA"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/978-1-4939-7101-5_60","volume-title":"Encyclopedia of AIDS","author":"F Kirchhoff","year":"2018","unstructured":"Kirchhoff F. HIV life cycle: Overview. In: Hope TJ, Richman DD, Stevenson M, editors. Encyclopedia of AIDS. Springer; 2018. p. 722\u201330."},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.cell.2008.05.005","volume":"133","author":"CM Swanson","year":"2008","unstructured":"Swanson CM, Malim MH. Snapshot: HIV-1 proteins. Cell. 2008;133:742. https:\/\/doi.org\/10.1016\/j.cell.2008.05.005.","journal-title":"Cell"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.chom.2010.06.004","volume":"8","author":"F Kirchhoff","year":"2010","unstructured":"Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. 2010;8:55\u201367. https:\/\/doi.org\/10.1016\/j.chom.2010.06.004.","journal-title":"Cell Host Microbe"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jmb.2011.04.021","volume":"410","author":"JAG Briggs","year":"2011","unstructured":"Briggs JAG, Kraeusslich H-G. The molecular architecture of HIV. J Mol Biol. 2011;410:491\u2013500. https:\/\/doi.org\/10.1016\/j.jmb.2011.04.021.","journal-title":"J Mol Biol"},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/COH.0b013e32832e6184","volume":"4","author":"WR Schief","year":"2009","unstructured":"Schief WR, Ban YE, Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS. 2009;4:431\u201340. https:\/\/doi.org\/10.1097\/COH.0b013e32832e6184.","journal-title":"Curr Opin HIV AIDS"},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature13036","volume":"509","author":"NA Doria-Rose","year":"2014","unstructured":"Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509:55\u201362. https:\/\/doi.org\/10.1038\/nature13036.","journal-title":"Nature"},{"key":"863_CR12","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","volume":"165","author":"Y Huang","year":"2016","unstructured":"Huang Y, Yu J, Lanzi A, et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell. 2016;165:1621\u201331. https:\/\/doi.org\/10.1016\/j.cell.2016.05.024.","journal-title":"Cell"},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.32607\/20758251-2015-7-4-11-21","volume":"7","author":"DN Shcherbakov","year":"2015","unstructured":"Shcherbakov DN, Bakulina AY, Karpenko LI, Ilyichev AA. Broadly neutralizing antibodies against HIV-1 as a novel aspect of the immune response. Acta Nat. 2015;7:11\u201321.","journal-title":"Acta Nat"},{"key":"863_CR14","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1128\/jvi.02658-10","volume":"85","author":"PL Moore","year":"2011","unstructured":"Moore PL, Gray ES, Sheward D, et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011;85:3128\u201341. https:\/\/doi.org\/10.1128\/jvi.02658-10.","journal-title":"J Virol"},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","volume":"173","author":"MM Sajadi","year":"2018","unstructured":"Sajadi MM, Dashti A, Rikhtegaran Tehrani Z, et al. Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses. Cell. 2018;173:1783-1795.e14. https:\/\/doi.org\/10.1016\/j.cell.2018.03.061.","journal-title":"Cell"},{"key":"863_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.710044","volume":"12","author":"DCC Hsu","year":"2021","unstructured":"Hsu DCC, Mellors JWW, Vasan S. Can broadly neutralizing HIV-1 antibodies help achieve an ART-free remission? Front Immunol. 2021;12:710044. https:\/\/doi.org\/10.3389\/fimmu.2021.710044.","journal-title":"Front Immunol"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/14760584.2014.894469","volume":"13","author":"M Medina-Ram\u00edrez","year":"2014","unstructured":"Medina-Ram\u00edrez M, Sanders RW, Klasse PJ. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? Expert Rev Vaccines. 2014;13:449\u201352. https:\/\/doi.org\/10.1586\/14760584.2014.894469.","journal-title":"Expert Rev Vaccines"},{"key":"863_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004329","volume":"21","author":"SR Walsh","year":"2024","unstructured":"Walsh SR, Gay CL, Karuna ST, et al. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127\/HPTN 087): a phase I randomized clinical trial. PLoS Med. 2024;21:e1004329. https:\/\/doi.org\/10.1371\/journal.pmed.1004329.","journal-title":"PLoS Med"},{"key":"863_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1086\/526786","volume":"197","author":"F Pereyra","year":"2008","unstructured":"Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563\u201371. https:\/\/doi.org\/10.1086\/526786.","journal-title":"J Infect Dis"},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/qad.0000000000000049","volume":"28","author":"D Gurdasani","year":"2014","unstructured":"Gurdasani D, Iles L, Dillon DG, et al. A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS. 2014;28:149\u201362. https:\/\/doi.org\/10.1097\/qad.0000000000000049.","journal-title":"AIDS"},{"key":"863_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103118","volume":"62","author":"BA Woldemeskel","year":"2020","unstructured":"Woldemeskel BA, Kwaa AK, Blankson JN. Viral reservoirs in elite controllers of HIV-1 infection: implications for HIV cure strategies. EBioMedicine. 2020;62:103118. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103118.","journal-title":"EBioMedicine"},{"key":"863_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/COH.0b013e328345a328","volume":"6","author":"B Autran","year":"2011","unstructured":"Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011;6:181\u20137. https:\/\/doi.org\/10.1097\/COH.0b013e328345a328.","journal-title":"Curr Opin HIV AIDS"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","volume":"27","author":"SG Deeks","year":"2007","unstructured":"Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406\u201316. https:\/\/doi.org\/10.1016\/j.immuni.2007.08.010.","journal-title":"Immunity"},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1126\/science.1143767","volume":"317","author":"J Fellay","year":"2007","unstructured":"Fellay J, Shianna KV, Ge DL, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317:944\u20137. https:\/\/doi.org\/10.1126\/science.1143767.","journal-title":"Science"},{"key":"863_CR25","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1126\/science.1195271","volume":"330","author":"F Pereyra","year":"2010","unstructured":"Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330:1551\u20137. https:\/\/doi.org\/10.1126\/science.1195271.","journal-title":"Science"},{"key":"863_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879124","volume":"13","author":"NF Bernard","year":"2022","unstructured":"Bernard NF, Kant S, Kiani Z, Tremblay C, Dupuy FP. Natural killer cells in antibody independent and antibody dependent HIV control. Front Immunol. 2022;13:879124. https:\/\/doi.org\/10.3389\/fimmu.2022.879124.","journal-title":"Front Immunol"},{"key":"863_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/infdis\/jiw163","volume":"214","author":"CM Buckner","year":"2016","unstructured":"Buckner CM, Kardava L, Zhang X, et al. Maintenance of HIV-specific memory B-cell responses in elite controllers despite low viral burdens. J Infect Dis. 2016;214:390\u20138. https:\/\/doi.org\/10.1093\/infdis\/jiw163.","journal-title":"J Infect Dis"},{"key":"863_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ebiom.2017.05.029","volume":"21","author":"A Rouers","year":"2017","unstructured":"Rouers A, Klingler J, Su B, et al. HIV-specific B cell frequency correlates with neutralization breadth in patients naturally controlling HIV-infection. EBioMedicine. 2017;21:158\u201369. https:\/\/doi.org\/10.1016\/j.ebiom.2017.05.029.","journal-title":"EBioMedicine"},{"key":"863_CR29","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1073\/pnas.0813392106","volume":"106","author":"YJ Guan","year":"2009","unstructured":"Guan YJ, Sajadi MM, Kamin-Lewis R, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci USA. 2009;106:3952\u20137. https:\/\/doi.org\/10.1073\/pnas.0813392106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"863_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12509","volume":"275","author":"M Bonsignori","year":"2017","unstructured":"Bonsignori M, Liao HX, Gao F, et al. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev. 2017;275:145\u201360. https:\/\/doi.org\/10.1111\/imr.12509.","journal-title":"Immunol Rev"},{"key":"863_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/QAI.0b013e3182100c1b","volume":"57","author":"MM Sajadi","year":"2011","unstructured":"Sajadi MM, Guan YJ, DeVico AL, et al. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. JAIDS J Acquir Immune Defic Syndr. 2011;57:9\u201315. https:\/\/doi.org\/10.1097\/QAI.0b013e3182100c1b.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"863_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193773","volume":"13","author":"N Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez N, McKee K, Lynch RM, et al. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE. 2018;13:e0193773. https:\/\/doi.org\/10.1371\/journal.pone.0193773.","journal-title":"PLoS ONE"},{"key":"863_CR33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212045","volume":"219","author":"V Lorin","year":"2022","unstructured":"Lorin V, Fern\u00e1ndez I, Masse-Ranson G, et al. Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. J Exp Med. 2022;219:e20212045. https:\/\/doi.org\/10.1084\/jem.20212045.","journal-title":"J Exp Med"},{"key":"863_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal2144","volume":"9","author":"NT Freund","year":"2017","unstructured":"Freund NT, Wang H, Scharf L, et al. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci Transl Med. 2017;9:eaal2144. https:\/\/doi.org\/10.1126\/scitranslmed.aal2144.","journal-title":"Sci Transl Med"},{"key":"863_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/coh.0000000000000554","volume":"14","author":"A Moris","year":"2019","unstructured":"Moris A, Pereira M, Chakrabarti L. A role for antibodies in natural HIV control. Curr Opin HIV AIDS. 2019;14:265\u201372. https:\/\/doi.org\/10.1097\/coh.0000000000000554.","journal-title":"Curr Opin HIV AIDS"},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1128\/jvi.01328-08","volume":"83","author":"M Mahalanabis","year":"2009","unstructured":"Mahalanabis M, Jayaraman P, Miura T, et al. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol. 2009;83:662\u201372. https:\/\/doi.org\/10.1128\/jvi.01328-08.","journal-title":"J Virol"},{"key":"863_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11904-016-0299-7","volume":"13","author":"KE Stephenson","year":"2016","unstructured":"Stephenson KE, Barouch DH. Broadly neutralizing antibodies for HIV eradication. Curr HIV AIDS Rep. 2016;13:31\u20137. https:\/\/doi.org\/10.1007\/s11904-016-0299-7.","journal-title":"Curr HIV AIDS Rep"},{"key":"863_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","volume":"326","author":"LM Walker","year":"2009","unstructured":"Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science. 2009;326:285\u20139. https:\/\/doi.org\/10.1126\/science.1178746.","journal-title":"Science"},{"key":"863_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1374913","volume":"15","author":"P Yu","year":"2024","unstructured":"Yu P, Ran J, Yang R, et al. Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2. Front Immunol. 2024;15:1374913. https:\/\/doi.org\/10.3389\/fimmu.2024.1374913.","journal-title":"Front Immunol"},{"key":"863_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113204","volume":"142","author":"Y Wu","year":"2024","unstructured":"Wu Y, Ji X, Yang Y, Wu B. Discovery of a fully human antibody to the proximal membrane terminus of MUC1 based on a B-cell high-throughput screening technique. Int Immunopharmacol. 2024;142:113204. https:\/\/doi.org\/10.1016\/j.intimp.2024.113204.","journal-title":"Int Immunopharmacol"},{"key":"863_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2501637122","volume":"122","author":"C Fan","year":"2025","unstructured":"Fan C, Keeffe JR, Malecek KE, et al. Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles. Proc Natl Acad Sci U S A. 2025;122:e2501637122. https:\/\/doi.org\/10.1073\/pnas.2501637122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"863_CR42","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1086\/605446","volume":"200","author":"F Pereyra","year":"2009","unstructured":"Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200:984\u201390. https:\/\/doi.org\/10.1086\/605446.","journal-title":"J Infect Dis"},{"key":"863_CR43","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62648","volume":"10","author":"D Cizmeci","year":"2021","unstructured":"Cizmeci D, Lofano G, Rossignol E, et al. Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. Elife. 2021;10:e62648. https:\/\/doi.org\/10.7554\/eLife.62648.","journal-title":"Elife"},{"key":"863_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41590-019-0581-0","volume":"21","author":"KM Roskin","year":"2020","unstructured":"Roskin KM, Jackson KJL, Lee JY, et al. Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. Nat Immunol. 2020;21:199\u2013209. https:\/\/doi.org\/10.1038\/s41590-019-0581-0.","journal-title":"Nat Immunol"},{"key":"863_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/QAD.0b013e328329f97d","volume":"23","author":"O Lambotte","year":"2009","unstructured":"Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and anti body-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009;23:897\u2013906. https:\/\/doi.org\/10.1097\/QAD.0b013e328329f97d.","journal-title":"AIDS"},{"key":"863_CR46","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1128\/jvi.01482-09","volume":"84","author":"NA Doria-Rose","year":"2010","unstructured":"Doria-Rose NA, Klein RM, Daniels MG, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010;84:1631\u20136. https:\/\/doi.org\/10.1128\/jvi.01482-09.","journal-title":"J Virol"},{"key":"863_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583820","volume":"11","author":"S Kant","year":"2020","unstructured":"Kant S, Zhang NY, Barb\u00e9 A, et al. Polyfunctional Fc dependent activity of antibodies to native trimeric envelope in HIV elite controllers. Front Immunol. 2020;11:583820. https:\/\/doi.org\/10.3389\/fimmu.2020.583820.","journal-title":"Front Immunol"},{"key":"863_CR48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chom.2019.09.016","volume":"26","author":"D Pinto","year":"2019","unstructured":"Pinto D, Fenwick C, Caillat C, et al. Structural basis for broad HIV-1 neutralization by the MPER-specific human broadly neutralizing antibody LN01. Cell Host Microbe. 2019;26:623\u201337. https:\/\/doi.org\/10.1016\/j.chom.2019.09.016.","journal-title":"Cell Host Microbe"},{"key":"863_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01590","volume":"8","author":"LM Mayr","year":"2017","unstructured":"Mayr LM, Su B, Moog C. Non-neutralizing antibodies directed against HIV and their functions. Front Immunol. 2017;8:1590. https:\/\/doi.org\/10.3389\/fimmu.2017.01590.","journal-title":"Front Immunol"},{"issue":"1","key":"863_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12883-6","volume":"7","author":"LM Mayr","year":"2017","unstructured":"Mayr LM, Decoville T, Schmidt S, et al. Non-neutralizing antibodies targeting the V1V2 domain of HIV exhibit strong antibody-dependent cell-mediated cytotoxic activity. Sci Rep. 2017;7(1):12655. https:\/\/doi.org\/10.1038\/s41598-017-12883-6.","journal-title":"Sci Rep"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00863-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:22:42Z","timestamp":1776723762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12981-026-00863-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00863-8","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China (Approval No. 2025KY079).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all study participants prior to enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"50"}}